A Review of 11 Years of Stenotrophomonas maltophilia Blood Isolates at a Tertiary Care Institute in Canada
BACKGROUND: Stenotrophomonas maltophilia has emerged as a significant nosocomial pathogen with increasing resistance to trimethoprim/sulphamethoxazole (TMP/SMX), the current drug of choice for treatment.
Saved in:
Main Authors: | Prenilla Naidu, Stephanie Smith |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2012/762571 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recurrent Hemoptysis with Penicillium Marneffei and Stenotrophomonas Maltophilia in Job’s Syndrome
by: Bosco HM Ma, et al.
Published: (2009-01-01) -
Pseudo-, Xantho-, and now Stenotrophomonas maltophilia: New Kid on the Block
by: JM Conly, et al.
Published: (1996-01-01) -
Epidemiology and Antimicrobial Resistance of Stenotrophomonas maltophilia in China, 2014–2021
by: Hanli Wang, et al.
Published: (2024-12-01) -
Antibiotic Resistance and Virulence Factors in Clinical Isolates of Stenotrophomonas maltophilia from Hospitalized Patients in Tehran, Iran
by: Mahrokh Bahrami, et al.
Published: (2024-01-01) -
Clinical and Optical Coherence Tomography Angiographic Features in Patients with Postcataract Stenotrophomonas maltophilia Endophthalmitis
by: Lu Chen, et al.
Published: (2020-01-01)